최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기International journal of molecular sciences, v.21 no.18, 2020년, pp.6826 -
Yoon, Hye Ree , Balupuri, Anand , Choi, Kwang-Eun , Kang, Nam Sook
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase with diverse functions in cell regulation. Abnormal expression and activity of DYRK1A contribute to numerous human malignancies, Down syndrome, and Alzheimer’s disease. Notably, DYRK1A has been proposed ...
1. Ferguson F.M. Gray N.S. Kinase inhibitors: The road ahead Nat. Rev. Drug Discov. 2018 17 353 377 10.1038/nrd.2018.21 29545548
2. Abbassi R. Johns T.G. Kassiou M. Munoz L. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications Pharmacol. Ther. 2015 151 87 98 10.1016/j.pharmthera.2015.03.004 25795597
3. Arbones M.L. Thomazeau A. Nakano-Kobayashi A. Hagiwara M. Arbones M.L. DYRK1A and cognition: A lifelong relationship Pharmacol. Ther. 2019 194 199 221 10.1016/j.pharmthera.2018.09.010 30268771
4. Boichuk S. Parry J.A. Makielski K.R. Litovchick L. Baron J.L. Zewe J.P. Mehalek K.R. Korzeniewski N. Seneviratne D.S. Schoffski P. The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis Cancer Res. 2013 73 5120 5129 10.1158/0008-5472.CAN-13-0579 23786773
5. Lee K.-S. Choi M. Kwon D.-W. Kim D. Choi J.-M. Kim A.-K. Ham Y. Han S.-B. Cho S. Cheon C.K. A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay Sci. Rep. 2020 10 1 10 10.1038/s41598-020-66750-y 31913322
6. Zhou Q. Phoa A.F. Abbassi R. Hoque M. Reekie T. Font J.S. Ryan R.M. Stringer B.W. Day B.W. Johns T.G. Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma J. Med. Chem. 2017 60 2052 2070 10.1021/acs.jmedchem.6b01840 28206758
7. Liu Q. Liu N. Zang S. Liu H. Wang P. Ji C. Sun X. Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc PLoS ONE 2014 9 e98853 10.1371/journal.pone.0098853 24901999
8. Dirice E. Walpita D. Vetere A. Meier B.C. Kahraman S. Hu J. Danik V. Burns S.M. Gilbert T.J. Olson D.E. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation Diabetes 2016 65 1660 1671 10.2337/db15-1127 26953159
9. Shen W. Taylor B. Jin Q. Nguyen-Tran V. Meeusen S. Zhang Y.-Q. Kamireddy A. Swafford A. Powers A.F. Walker J. Inhibition of DYRK1A and GSK3B induces human β-cell proliferation Nat. Commun. 2015 6 8372 10.1038/ncomms9372 26496802
10. Wang P. Alvarez-Perez J.C. Felsenfeld D.P. Liu H. Sivendran S. Bender A. Kumar A. Sanchez R. Scott N.K. Garcia-Ocana A. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication Nat. Med. 2015 21 383 388 10.1038/nm.3820 25751815
11. Rachdi L. Kariyawasam D. Aiello V. Herault Y. Janel N. Delabar J.-M. Polak M. Scharfmann R. Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance Cell Cycle 2014 13 2221 2229 10.4161/cc.29250 24870561
12. Abdolazimi Y. Zhao Z. Lee S. Xu H. Allegretti P. Horton T.M. Yeh B. Moeller H.P. Nichols R.J. McCutcheon D. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition Endocrinology 2018 159 3143 3157 10.1210/en.2018-00083 29514186
13. Jarhad D.B. Mashelkar K.K. Kim H.-R. Noh M. Jeong L.S. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics J. Med. Chem. 2018 61 9791 9810 10.1021/acs.jmedchem.8b00185 29985601
14. Ahmad I. Fakhri S. Khan H. Jeandet P. Aschner M. Yu Z.-L. Targeting cell cycle by β-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer Chem. Biol. 2020 330 109229 10.1016/j.cbi.2020.109229
15. Naert G. Ferre V. Meunier J. Keller E. Malmstrom S. Givalois L. Carreaux F. Bazureau J.-P. Maurice T. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25?35 peptide administration in mice Eur. Neuropsychopharmacol. 2015 25 2170 2182 10.1016/j.euroneuro.2015.03.018 26381812
16. Sarno S. Mazzorana M. Traynor R. Ruzzene M. Cozza G. Pagano M.A. Meggio F. Zagotto G. Battistutta R. Pinna L.A. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: Role of a nitro group that discriminates between CK2 and DYRK1A Cell. Mol. Life Sci. 2011 69 449 460 10.1007/s00018-011-0758-7 21720886
17. Leal F.D. Lima C.H. De Alencastro R.B. Castro H.C. Rodrigues C.R. Albuquerque M.G. Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer’s Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme Int. J. Mol. Sci. 2015 16 5235 10.3390/ijms16035235 25756379
18. Guedj F. Sebrie C. Rivals I. Ledru A. Paly E. Bizot J.C. Smith D. Rubin E. Gillet B. Arbones M.L. Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A PLoS ONE 2009 4 e4606 10.1371/journal.pone.0004606 19242551
19. Stotani S. Giordanetto F. Medda F. DYRK1A inhibition as potential treatment for Alzheimer’s disease Futur. Med. Chem. 2016 8 681 696 10.4155/fmc-2016-0013
20. Kumar K. Ung P.M.-U. Wang P. Wang H. Li H. Andrews M.K. Stewart A.F. Schlessinger A. DeVita R.J. Novel Selective Thiadiazine DYRK1A Inhibitor Lead Scaffold with Human Pancreatic β-cell Proliferation Activity Eur. J. Med. Chem. 2018 157 1005 1016 10.1016/j.ejmech.2018.08.007 30170319
21. Ogawa Y. Nonaka Y. Goto T. Ohnishi E. Hiramatsu T. Kii I. Yoshida M. Ikura T. Onogi H. Shibuya H. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A Nat. Commun. 2010 1 1 9 10.1038/ncomms1090 20975674
22. Gourdain S. Dairou J. Denhez C. Bui L.C. Rodrigues-Lima F. Janel N. Delabar J.M. Cariou K. Dodd R.H. Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity J. Med. Chem. 2013 56 9569 9585 10.1021/jm401049v 24188002
23. Kii I. Sumida Y. Goto T. Sonamoto R. Okuno Y. Yoshida S. Kato-Sumida T. Koike Y. Abe M. Nonaka Y. Selective inhibition of the kinase DYRK1A by targeting its folding process Nat. Commun. 2016 7 11391 10.1038/ncomms11391 27102360
24. Rosenthal A.S. Tanega C. Shen M. Mott B.T. Bougie J.M. Nguyen D.-T. Misteli T. Auld D.S. Maloney D.J. Thomas C.J. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk) Bioorganic Med. Chem. Lett. 2011 21 3152 3158 10.1016/j.bmcl.2011.02.114 21450467
25. Pathak A. Rohilla A. Gupta T. Akhtar J. Haider R. Sharma K. Haider K. Yar M.S. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective Eur. J. Med. Chem. 2018 158 559 592 10.1016/j.ejmech.2018.08.093 30243157
26. Giraud F. Alves G. Debiton E. Nauton L. Thery V. Durieu E. Ferandin Y. Lozach O. Meijera L. Anizon F. Synthesis, Protein Kinase Inhibitory Potencies, and in Vitro Antiproliferative Activities of Meridianin Derivatives J. Med. Chem. 2011 54 4474 4489 10.1021/jm200464w 21623630
27. Kassis P. Brzeszcz J. Beneteau V. Lozach O. Meijera L. Le Guevel R. Guillouzo C. Lewiski K. Bourg S. Colliandre L. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents Eur. J. Med. Chem. 2011 46 5416 5434 10.1016/j.ejmech.2011.08.048 21944287
28. Neagoie C. Vedrenne E. Buron F. Merour J.-Y. Roca S. Bourg S. Lozach O. Meijera L. Baldeyrou B. Lansiaux A. Synthesis of chromeno[3¨C-b]indoles as Lamellarin D analogues: A novel DYRK1A inhibitor class Eur. J. Med. Chem. 2012 49 379 396 10.1016/j.ejmech.2012.01.040 22305342
29. Falke H. Chaikuad A. Becker A. Loaec N. Lozach O. Abu Jhaisha S. Becker W. Jones P.G. Preu L. Baumann K. 10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A J. Med. Chem. 2015 58 3131 3143 10.1021/jm501994d 25730262
30. Foucourt A. Hedou D. Dubouilh-Benard C. Desire L. Casagrande A.-S. Leblond B. Loaec N. Meijer L. Besson T. Design and synthesis of thiazolo [5, 4-f] quinazolines as DYRK1A inhibitors, part I Molecules 2014 19 5546 10.3390/molecules191015546
31. Meine R. Becker W. Falke H. Preu L. Loaec N. Meijera L. Kunick C. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design Molecules 2018 23 64 10.3390/molecules23020064 29364148
32. Jang W.D. Kim J.-T. Kang N.S. The analysis of water network for kinase selectivity based on the MD simulations J. Mol. Liq. 2014 191 37 41 10.1016/j.molliq.2013.11.023
33. Jang W.D. Lee M.H. Kang N.S. Quantitative assessment of kinase selectivity based the water-ring network in protein binding sites using molecular dynamics simulations J. Mol. Liq. 2016 221 316 322 10.1016/j.molliq.2016.06.013
34. Lee M.H. Balupuri A. Jung Y.-R. Choi S. Lee A. Cho Y.S. Kang N.S. Design of a Novel and Selective IRAK4 Inhibitor Using Topological Water Network Analysis and Molecular Modeling Approaches Molecules 2018 23 3136 10.3390/molecules23123136 30501110
35. Lee M.H. Lee D.-Y. Balupuri A. Jeong J.-W. Kang N.S. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin Molecules 2019 24 2808 10.3390/molecules24152808
36. Balupuri A. Choi K.-E. Kang N.S. Computational insights into the role of α-strand/sheet in aggregation of α-synuclein Sci. Rep. 2019 9 59 10.1038/s41598-018-37276-1 30635607
37. Choi K.-E. Chae E. Balupuri A. Yoon H.R. Kang N.S. Topological Water Network Analysis Around Amino Acids Molecules 2019 24 2653 10.3390/molecules24142653
38. Karaman M.W. Herrgard S. Treiber D.K. Gallant P. Atteridge C.E. Campbell B.T. Chan K.W. Ciceri P. Davis M.I. Edeen P.T. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008 26 127 132 10.1038/nbt1358 18183025
39. Bertrand J. Thieffine S. Vulpetti A. Cristiani C. Valsasina B. Knapp S. Kalisz H. Flocco M. Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors J. Mol. Biol. 2003 333 393 407 10.1016/j.jmb.2003.08.031 14529625
40. Xue J. Zhang L. Xie X. Gao Y. Jiang L. Wang J. Wang Y. Gao R. Yu J. Xiao H. Prenatal bisphenol A exposure contributes to Tau pathology: Potential roles of CDK5/GSK3β/PP2A axis in BPA-induced neurotoxicity Toxicology 2020 438 152442 10.1016/j.tox.2020.152442 32278051
41. Georgievska B. Sandin J. Doherty J. Mortberg A. Neelissen J. Andersson A. Gruber S. Nilsson Y. Schott P. Arvidsson P.I. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans J. Neurochem. 2013 125 446 456 10.1111/jnc.12203 23410232
42. Brown D.G. Shorter J. Wobst H.J. Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia Bioorganic Med. Chem. Lett. 2019 30 126942 10.1016/j.bmcl.2019.126942
43. Koyama T. Yamaotsu N. Nakagome I. Ozawa S.-I. Yoshida T. Hayakawa D. Hirono S. Multi-step virtual screening to develop selective DYRK1A inhibitors J. Mol. Graph. Model. 2017 72 229 239 10.1016/j.jmgm.2017.01.014 28129593
44. Li S. Sun X. Wu H. Yu P. Wang X. Jiang Z. Gao E. Chen J. Li D. Qiu C. TRPA1 Promotes Cardiac Myofibroblast Transdifferentiation after Myocardial Infarction Injury via the Calcineurin-NFAT-DYRK1A Signaling Pathway Oxidative Med. Cell. Longev. 2019 2019 6408352 10.1155/2019/6408352 31217840
45. Chen J.-Y. Lin J.-R. Tsai F.-C. Meyer T. Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle Mol. Cell 2013 52 87 100 10.1016/j.molcel.2013.09.009 24119401
46. Pronk S. Pall S. Schulz R. Larsson P. Bjelkmar P. Apostolov R. Shirts M.R. Smith J.C. Kasson P.M. Van Der Spoel D. GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit Bioinformatics 2013 29 845 854 10.1093/bioinformatics/btt055 23407358
47. Brooks B.R. Bruccoleri R.E. Olafson B.D. States D.J. Swaminathan S. Karplus M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations J. Comput. Chem. 1983 4 187 217 10.1002/jcc.540040211
48. Jorgensen W.L. Chandrasekhar J. Madura J.D. Impey R.W. Klein M.L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983 79 926 935 10.1063/1.445869
49. Bussi G. Donadio D. Parrinello M. Canonical sampling through velocity rescaling J. Chem. Phys. 2007 126 014101 10.1063/1.2408420 17212484
50. Nose S. Klein M. Constant pressure molecular dynamics for molecular systems Mol. Phys. 1983 50 1055 1076 10.1080/00268978300102851
51. Hess B. Bekker H. Berendsen H.J. Fraaije J.G. LINCS: A linear constraint solver for molecular simulations J. Comput. Chem. 1997 18 1463 1472 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
52. Darden T. York D. Pedersen L. Particle mesh Ewald: AnN?log(N) method for Ewald sums in large systems J. Chem. Phys. 1993 98 10089 10092 10.1063/1.464397
53. Brakoulias A. Jackson R.M. Towards a structural classification of phosphate binding sites in protein-nucleotide complexes: An automated all-against-all structural comparison using geometric matching Proteins Struct. Funct. Bioinform. 2004 56 250 260 10.1002/prot.20123 15211509
54. Kinnings S.L. Jackson R.M. Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family J. Chem. Inf. Model. 2009 49 318 329 10.1021/ci800289y 19434833
55. Ballester P.J. Richards W.G. Ultrafast shape recognition for similarity search in molecular databases Proc. R. Soc. A Math. Phys. Eng. Sci. 2007 463 1307 1321 10.1098/rspa.2007.1823
56. Venkatachalam C. Jiang X. Oldfield T. Waldman M. LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites J. Mol. Graph. Model. 2003 21 289 307 10.1016/S1093-3263(02)00164-X 12479928
57. Jang W.D. Kim J.-T. Son H.Y. Park S.Y. Cho Y.S. Koo T.-S. Lee H. Kang N.S. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design Bioorganic Med. Chem. Lett. 2015 25 3947 3952 10.1016/j.bmcl.2015.07.037
58. Uzdensky A. Apoptosis regulation in the penumbra after ischemic stroke: Expression of pro- and antiapoptotic proteins Apoptosis 2019 24 687 702 10.1007/s10495-019-01556-6 31256300
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.